vs

Side-by-side financial comparison of Arcutis Biotherapeutics, Inc. (ARQT) and Ategrity Specialty Insurance Co Holdings (ASIC). Click either name above to swap in a different company.

Arcutis Biotherapeutics, Inc. is the larger business by last-quarter revenue ($129.5M vs $116.1M, roughly 1.1× Ategrity Specialty Insurance Co Holdings). Ategrity Specialty Insurance Co Holdings runs the higher net margin — 19.5% vs 13.4%, a 6.1% gap on every dollar of revenue.

Arcutis Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative prescription therapies for immune-mediated dermatological diseases. Its core product portfolio targets conditions including psoriasis, atopic dermatitis, and alopecia areata, primarily serving patients and healthcare providers across the United States, addressing unmet needs in the dermatology care segment.

Ategrity Specialty Insurance Co Holdings is a specialty insurance holding company that provides commercial property and casualty insurance solutions. It primarily focuses on excess and surplus lines coverage, serving niche segments including construction, healthcare, and small business markets across the United States, offering tailored policies for unique, hard-to-place risks that standard carriers do not typically cover.

ARQT vs ASIC — Head-to-Head

Bigger by revenue
ARQT
ARQT
1.1× larger
ARQT
$129.5M
$116.1M
ASIC
Higher net margin
ASIC
ASIC
6.1% more per $
ASIC
19.5%
13.4%
ARQT

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
ARQT
ARQT
ASIC
ASIC
Revenue
$129.5M
$116.1M
Net Profit
$17.4M
$22.7M
Gross Margin
91.0%
Operating Margin
14.2%
25.6%
Net Margin
13.4%
19.5%
Revenue YoY
81.5%
Net Profit YoY
261.2%
EPS (diluted)
$0.14
$0.45

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ARQT
ARQT
ASIC
ASIC
Q4 25
$129.5M
Q3 25
$99.2M
$116.1M
Q2 25
$81.5M
$101.8M
Q1 25
$65.8M
Q4 24
$71.4M
Q3 24
$44.8M
Q2 24
$30.9M
Q1 24
$49.6M
Net Profit
ARQT
ARQT
ASIC
ASIC
Q4 25
$17.4M
Q3 25
$7.4M
$22.7M
Q2 25
$-15.9M
$17.6M
Q1 25
$-25.1M
Q4 24
$-10.8M
Q3 24
$-41.5M
Q2 24
$-52.3M
Q1 24
$-35.4M
Gross Margin
ARQT
ARQT
ASIC
ASIC
Q4 25
91.0%
Q3 25
91.2%
Q2 25
90.8%
Q1 25
86.6%
Q4 24
90.3%
Q3 24
87.7%
Q2 24
88.8%
Q1 24
93.4%
Operating Margin
ARQT
ARQT
ASIC
ASIC
Q4 25
14.2%
Q3 25
8.6%
25.6%
Q2 25
-17.9%
21.9%
Q1 25
-37.3%
Q4 24
-10.7%
Q3 24
-87.3%
Q2 24
-162.3%
Q1 24
-63.8%
Net Margin
ARQT
ARQT
ASIC
ASIC
Q4 25
13.4%
Q3 25
7.5%
19.5%
Q2 25
-19.5%
17.3%
Q1 25
-38.1%
Q4 24
-15.1%
Q3 24
-92.8%
Q2 24
-169.6%
Q1 24
-71.4%
EPS (diluted)
ARQT
ARQT
ASIC
ASIC
Q4 25
$0.14
Q3 25
$0.06
$0.45
Q2 25
$-0.13
$0.39
Q1 25
$-0.20
Q4 24
$-0.09
Q3 24
$-0.33
Q2 24
$-0.42
Q1 24
$-0.32

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ARQT
ARQT
ASIC
ASIC
Cash + ST InvestmentsLiquidity on hand
$42.9M
$34.3M
Total DebtLower is stronger
$109.0M
Stockholders' EquityBook value
$189.5M
$588.6M
Total Assets
$433.0M
$1.4B
Debt / EquityLower = less leverage
0.58×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ARQT
ARQT
ASIC
ASIC
Q4 25
$42.9M
Q3 25
$47.1M
$34.3M
Q2 25
$72.7M
$23.5M
Q1 25
$53.1M
Q4 24
$71.3M
Q3 24
$134.9M
Q2 24
$84.3M
Q1 24
$190.1M
Total Debt
ARQT
ARQT
ASIC
ASIC
Q4 25
$109.0M
Q3 25
$108.5M
Q2 25
$108.0M
Q1 25
$107.6M
Q4 24
$107.2M
Q3 24
$204.6M
Q2 24
$203.8M
Q1 24
$202.8M
Stockholders' Equity
ARQT
ARQT
ASIC
ASIC
Q4 25
$189.5M
Q3 25
$158.1M
$588.6M
Q2 25
$139.0M
$559.7M
Q1 25
$142.7M
Q4 24
$157.5M
Q3 24
$156.6M
Q2 24
$186.4M
Q1 24
$224.9M
Total Assets
ARQT
ARQT
ASIC
ASIC
Q4 25
$433.0M
Q3 25
$371.0M
$1.4B
Q2 25
$352.4M
$1.4B
Q1 25
$344.1M
Q4 24
$348.9M
Q3 24
$437.4M
Q2 24
$444.8M
Q1 24
$478.5M
Debt / Equity
ARQT
ARQT
ASIC
ASIC
Q4 25
0.58×
Q3 25
0.69×
Q2 25
0.78×
Q1 25
0.75×
Q4 24
0.68×
Q3 24
1.31×
Q2 24
1.09×
Q1 24
0.90×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ARQT
ARQT
ASIC
ASIC
Operating Cash FlowLast quarter
$26.2M
$41.1M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
1.51×
1.81×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ARQT
ARQT
ASIC
ASIC
Q4 25
$26.2M
Q3 25
$-1.8M
$41.1M
Q2 25
$324.0K
$50.8M
Q1 25
$-30.4M
Q4 24
$-748.0K
Q3 24
$-34.7M
Q2 24
$-45.1M
Q1 24
$-31.6M
Free Cash Flow
ARQT
ARQT
ASIC
ASIC
Q4 25
Q3 25
Q2 25
$246.0K
Q1 25
$-31.0M
Q4 24
Q3 24
$-34.8M
Q2 24
Q1 24
FCF Margin
ARQT
ARQT
ASIC
ASIC
Q4 25
Q3 25
Q2 25
0.3%
Q1 25
-47.1%
Q4 24
Q3 24
-77.8%
Q2 24
Q1 24
Capex Intensity
ARQT
ARQT
ASIC
ASIC
Q4 25
0.0%
Q3 25
0.0%
Q2 25
0.1%
Q1 25
0.9%
Q4 24
0.0%
Q3 24
0.3%
Q2 24
0.0%
Q1 24
0.0%
Cash Conversion
ARQT
ARQT
ASIC
ASIC
Q4 25
1.51×
Q3 25
-0.24×
1.81×
Q2 25
2.88×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons